MetrioPharm Press Releases
-
Steffen Stürzebecher, MD, PhD, Appointed New Chief Medical Officer at MetrioPharm
Steffen Stürzebecher, MD, PhD, takes on the position of Chief Medical Officer (CMO). He joins the management team of Thomas Christély, CEO, and Marcus Thelen, PhD, CSO. -
Press Release: MetrioPharm Announces Change to its Board of Directors
Mr Christoph von Moos has resigned from the Board of Directors of MetrioPharm AG.
-
Press Release: Prof. Dr. Marcus Thelen Joins MetrioPharm AG as Chief Scientific Officer (CSO)
Prof. Dr. Marcus Thelen has been appointed Chief Scientific Officer (CSO) and will strengthen MetrioPharm’s scientific development strategy.
-
MetrioPharm Announces Changes to its Board of Directors
Dr. Stephan Rietiker and Dr. Harald Fricke have stepped down with immediate effect. Jörg Gruber appointed as new Chairman of the Board of Directors.
-
MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
MetrioPharm AG announced today that MetrioPharm’s MP1032 received EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
-
Dr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG
MetrioPharm AG announced today that the new Board of Directors unanimously elected Dr. Stephan Rietiker as Chairman at its constituent meeting
-
Four new members elected to the Board of Directors of MetrioPharm AG
MetrioPharm AG announced today that four new members were elected to the Board of Directors at an Extraordinary General Meeting on April 17, 2025.
-
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
MetrioPharm AG today announced that it has established a Scientific Advisory Board (SAB). The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy.
-
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that results from its clinical trial CT-05 in hospitalised patients with moderate to severe COVID-19 have been published in the renowned journal The Lancet Regional Health – Europe.
-
MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
MetrioPharm AG announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for MP1032 for the treatment of Duchenne muscular dystrophy.